ClearPoint Neuro, Inc.

CLPTNASDAQHealthcare● Active

$12.93

+$0.04(+0.30%)

Market Cap$387714067

P/E Ratio—

52W High$30.1

52W Low$8.27

Avg Volume656K

Open$13.19

Beta1.31

Free Cash Flow Financials Revenue

ClearPoint Neuro, Inc. (CLPT) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CLPT · free cash flow · updated Jun 8, 2026

Core FCF metrics

CLPT · FCF · TTM · margin & CAGR

Free cash flow was −$24.4M for FY2025 (fiscal year ending 2025-12-31), down 165.0% year-over-year The FCF margin was -66.1%.

FY2025 Free Cash Flow−$24.4M▼ -165.0% YoY

Trailing 12M (TTM)−$26.7Mtrailing 4 quarters sum

FCF Margin-66.1%−$24.4M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

CLPT · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$23.9M(1M)−$24.4M▼ 165.0%-66.1%

FY2024−$8.9M(0M)−$9.2M▲ +36.1%-29.4%

FY2023−$13.7M(1M)−$14.4M▲ +12.1%-60.3%

FY2022−$16.2M(0M)−$16.4M▼ 27.6%-79.9%

FY2021−$12.7M(0M)−$12.9M▼ 55.2%-78.9%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

CLPT · P/FCF · FCF yield · FCF per share

ClearPoint Neuro, Inc. (CLPT) reported negative free cash flow of −$0.02B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

CLPT · cash flow statement · operating / investing / financing

For FY2025, ClearPoint Neuro, Inc. generated −$23.9M in operating cash flow and spent 1M in capital expenditures, yielding −$24.4M in free cash flow.

Operating Activities

−$23.9M

Cash from core business operations

2025-12-31

Investing Activities

+$0.6M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$50.2M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$23.9M) − |CapEx| (1M) = FCF (−$24.4M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

CLPT vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

ClearPoint Neuro, Inc.YOU

CLPT

−$24.4M-165.0%-66.1%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

ClearPoint Neuro, Inc. (CLPT) reported free cash flow of −$24.4M for FY2025 (fiscal year ending 2025-12-31), down 165.0% year-over-year. The FCF margin was -66.1%.

ClearPoint Neuro, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 15 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

CLPT free cash flow · 8 questions

ClearPoint Neuro, Inc. free cash flow was −$24.4M for FY2025, down 165.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$26.7M.

CLPT free cash flowCLPT FCFCLPT FCF 2025CLPT free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · ClearPoint Neuro, Inc. · ClearPoint Neuro, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026